Vandana Madkan, MD, FAAD
Board Certified Dermatologist, American Board of Dermatology

Dr. Vandana Madkan, the founder of Mosaic Dermatology, is a board certified dermatologist and fellow of the American Academy of Dermatology. She not only enjoys practicing the full breadth of medical, surgical and cosmetic dermatology, but also feels passionately about educating physicians and patients alike on the important aspects of medical to cosmetic skin health. She lectures nationally on the identification and treatment of skin disease and works actively with patient groups such as the National Psoriasis Foundation and National Alopecia Areata Foundation to promote new therapies for patients. Dr Madkan has also traveled to Cuba to study different health care systems and observe the implementation of psoralens and other plants in medicinal therapies.

She trained at the prestigious MD Anderson Cancer Center and the University of Texas Health Sciences Center where she served as chief resident in her final year. She then joined a locally well respected and academically inclined private practice in Houston where she was sub-investigator for the clinical trials that brought Humira to market for psoriasis in 2008 and was also principal investigator for the clinical trials that brought Otezla to market for psoriasis in 2015. She left Texas and returned to California, where she lived as a young child, in order to oversee the psoriasis clinic at UCLA where she was honored by the residency program as Outstanding Teacher of the Year. She left UCLA as Assistant Professor of Dermatology in 2013 to begin her own practice in Santa Monica and Beverly Hills in order to increasingly focus on patient care and expand on her previous clinical trial experience by opening a clinical trials center attached to an international consortium of trial physicians called Probity Medical Group.


Dr Madkan has an extensive list of published studies and articles in esteemed journals such as The Archives of Dermatology and The Journal of the American Academy of Dermatology  as well as chapters in Dermatology textbooks on the subjects of psoriasis, herpes, skin cancer, and cosmetic enhancements. She continues to expand her knowledge of treatments in order to provides her patients the latest and greatest in medical care.

Originally from Augusta, Georgia, Dr. Madkan received her undergraduate education at Emory University after which she completed her medical degree at the Medical College of Georgia.  The remainder of her medical training took her through an internship in internal medicine at the University of Maryland and Baltimore VA Medical Centers, a clinical research fellowship in virology, psoriasis and sexually transmitted diseases at the Center for Clinical Studies in Houston, and a residency in Dermatology at the University of Texas Health Science Center and MD Anderson Cancer Center.

In her spare time, she enjoys spending time with her husband at the beach and visiting with her close knit family. She is great fan of historical non fiction and as a literature major in undergrad, loves any books about people in medicine, including Cutting for Stone by Abraham Varghese. As a proud Angeleno, she is a staunch Laker fan through good, bad and horrific times, and remains on the list for season tickets.


(1996-2000) Bachelor of Arts in Literature, Emory University, Atlanta, Georgia
(2000-2004) Medical Doctorate, Georgia Health Sciences University, Medical College of Georgia, Augusta, GA
(2004-2005) Internal Medicine Preliminary Internship, The University of Maryland Medical Center & the Baltimore VA Medical Center, Baltimore, Maryland
(2005-2006) Clinical Research Fellowship in Virology, Psoriasis, and Sexually Transmitted Diseases, Center for Clinical Studies, Houston, Texas
(2007-2010) Dermatology Resident and Chief Resident, The University of Texas Medical School at Houston and MD Anderson Cancer Center, Department of Dermatology, Houston, Texas

Licensure / Certifications / Professional Memberships:

Licensure: (2013-Present) Medical License, California, # A124332, Expires 08/31/2018
(2005-2014) Medical License, Texas, # M2384, Expired 11/30/2014
(2010-Present) Diplomate, American Board of Dermatology (Board Certification)
(2005-Present) Advanced Cardiac Life Support/Basic Cardiac Life Support
United States Medical Licensing Examination Step 1,2,3: passed Professional Memberships: (2005-Present) American Academy of Dermatology
(2008-Present) Women’s Dermatologic Society
(2015-Present) The Photomedicine Society
(2000-2010, 2014-Present) American Medical Association
(2005-2013) Houston Dermatological Society
(2005-2013) Harris County Medical Society- Texas Medical Association
(2008-2010) American Society of Dermatologic Surgery
(2000-2004) American Medical Student Association

Professional Experience:

Professional Experience:
(2015-Present) Owner, Staff Dermatologist & Principal Investigator, Madkan Dermatology, Santa Monica, California
(2013-2015) Assistant Clinical Professor, Division of Dermatology, David Geffen School of Medicine, Los Angeles, California
(2010-2013) Staff Dermatologist & Principal Investigator for Clinical Studies, Dermatological Association of Texas and Center for Clinical Studies, Houston, Texas


1) Berthelot C, Madkan VK, Tyring Sk. Immunomodulators. IN: K. Nouri, ed. Skin Cancer. McGraw-Hill. 2006.
2) Madkan VK, Sra KK, Tyring SK. The Role of Mucosal Immunity in Protection against Viral Diseases. IN: SK Tyring, ed. Mucosal Immunology and Virology. London; Springer London Ltd, 2006.
3) Baro S, Madkan VK, Lozano A, Poast J, Guerro-Plata A, Garafalo RP, Tyring SK. Biological Basis of Interferons’ Actions and Uses. IN: K Chadha, ed. Interferons: Current Status, 2007.
4) Chang YC, Madkan VK, Sra KK, Carrasco DA, Lee PC, Tyring SK. Systemic Antiviral Agents for Therapy of Infections due to Human Herpesviruses and Human Immunodeficiency Virus. IN: SE Wolverton, ed. Comprehensive Dermatologic Drug Therapy 2nd edn. Saunders, 2007.
5) Madkan V, Sra K, Brantley J, Carrasco D, Mendoza N, Tyring SK. Human Herpesviruses. IN: J Bologna, J Jorizzo, R Rapini, eds. Dermatology 2nd ed. New York, NY: Elsevier, 2008.
6) Ahmed AM, Madkan VK, Brantley JS, Tyring SK. Nonvenereal Treponematoses. IN: P Brachman, E Abrutyn, eds. Bacterial Infections of Humans 4th ed. New York, NY: Springer, 2009.

1) Sheehan D, Madkan VK, Strickland W, Peterson C. Atrophic Dermatofibrosarcoma Protuberans: A Case Report and Reappraisal of the Literature. Cutis. 2004 Oct; 74(4):237-42.
2) Madkan VK, Bandow G, Koo JYM. Resolution of pruritus secondary to Polycythemia Vera in a patient treated with narrow-band ultraviolet B phototherapy. J Dermatolog Treat. 2005 Feb;16(1):56-7.
3) Madkan VK, Koo JYM. Demyelination and Neurological Sequelae in Etanercept and Infliximab Therapies: A Review of the Literature. Psoriasis Forum. 2005 Feb;11: 6-8.
4) Chang YC, Madkan VK, Cook-Norris RH, Sra KK, Tyring SK. Current and Potential Uses of Imiquimod. South Med J. 2005 Sep;98(9):914-20.
5) Madkan VK, Giancola AA, Sra KK, Tyring SK. Sex Differences in the Transmission, Prevention, and Disease Manifestations of Sexually Transmitted Diseases. Arch Dermatol. 2006 Mar;142(3);365-70.
6) Lupi O, Madkan VK, Tyring SK. Tropical Dermatology: Bacterial tropical diseases. J Am Acad Dermatol. 2006 Apr;54(4):559-78.
7) Ahmed AM, Madkan VK, Tyring SK. Human Papillomavirus and Genital Disease. Dermatol Clin. 2006 Jun;23(2).
8) Ahmed AM, Brantley JS, Madkan V, Mendoza N, Tyring SK. Managing herpes zoster in immuncompromised patients. Herpes. 2007 Sep;14(2):32-6.
9) Madkan VK, Cook-Norris RH, Tyring SK. The Oncogenic Potential of Human Papillomaviruses: An Update and Review on the Role of Host Genetics and Environmental Co-Factors. Br Journal Dermatol. 2007 Sep;157(3):634-5.
10) Kunishige JH, Hymes SR, Madkan VK, Uptmore D, Girault S, Lazar AJF, Rady P, Tyring SK. Case Report: Epidermodysplasia Verruciformis in the Setting of Graft-Versus-Host Dises. J Am Acad Dermatol. 2007 Nov; 57 (5 Suppl): S78-80.
11) Hicks LD, Cook-Norris RH, Mendoza N, Madkan V, Arora A, Tyring SK. Family history as a risk factor for herpes zoster: a case control study. Arch Dermatol. 2008 May;144(5):603-8.
12) Mays R, Gordon R, Wilson JM, LaPolla WJ, Sra KK, Madkan V, Tyring SK. Persistant erythematous plaque after minor trauma in an immunocompromised woman. Dermatol Online J. 2012 Apr 15;18 (4):2
13) Yamauchi P, Madkan V. DS-00352-2015 (Absence of Koebnerization Following Ablative and Non-Ablative Laser Therapy in Patients with Plaque Psoriasis) 2016 Jan.

Clinical Trials / Research Grants / Fellowships Received:

As Principal Investigator:
1) Apo-Pharma: “A 12-week Randomized, Double-blind, Placebo-controlled, Multicenter, Multiple Sequential Dose Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Apo805K1 in Subjects with Moderate to Severe Chronic Plaque Psoriasis.” 2011-Present.
2) Celgene: “A Phase 3, MultiCenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects with Moderate to Severe Plaque Psoriasis” 2011-Present.
3) Celgene: “A Phase 3, MultiCenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) In Subjects with Active Psoriatic Arthritis Who Have Not Been Previously Treated with Disease-Modifying Antirheumatic Drugs” 2011-Present.
4) Celgene: “Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, ParallelGroup, Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) In Subjects With Active Psoriatic Arthritis and A Qualifying and a Qualifying Psoriasis Lesion.” 2011-Present.
5) Galderma: “A Multi-center, Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel Group Study Comparing the Efficacy and Safety of CD2475/101 40mg Tablets versus Placebo and Doxycycline 100mg Capsules Once Daily in the Treatment of Inflammatory Lesions in Subjects with Acne Vulgaris” 2011-2012.

As Subinvestigator:
1) GlaxoSmithKline: ”An international, randomized, double-blind, placebo-controlled, multicenter, 6-month study of the efficacy and safety of valacyclovir 1g once daily vs. placebo for the suppression of HSV-2 genital herpes in newly diagnosed immunocompetent subjects.” 2004-2006.
2) GlaxoSmithKline: “A randomized, double-blind, placebo-controlled, multicenter, two-way crossover study to investigate the effect of Valtrex 1g once daily for 60 days on viral shedding in HSV-2 seropositive subjects with no previous history of symptomatic genital herpes infection.” 2004-2005.
3) Abbott:”A multicenter open-label continuation study in moderate to severe chronic plaque psoriasis subjects who completed a proceeding psoriasis clinical study with Adalimumab.” 2005-2007.
4) Corgentech-PK: “A phase 1/2 multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study to evaluate the safety of repeated topical application of three concentrations of NF-kappaB decoy in adults with mild-to-moderate atopic dermatitis.” 2005-2006.
5) Abbott: “A phase II, multi-center, randomized, double-blind, placebo-controlled study comparing the safety and efficacy of subcutaneous injections of ABT-874 vs. placebo in subjects with moderate to severe chronic plaque psoriasis.” 2005-2007.
6) GlaxoSmithKline: “A double-blind, randomized, controlled Phase III study to assess the prophylactic efficacy and safety of gD-Alum/MPL vaccine in the prevention of genital herpes disease in young women who are HSV-1 and -2 seronegative.” 2006-2008.
7) Merck: “ A multi-center, double-blind, randomized, placebo-controlled phase II proof-of-concept study to evaluate the safety and efficacy of a 3-dose regimen of the Merck Adenovirus serotype 5 HIV-1 gag/pol/nef vaccine in adults at high risk of HIV-1 infection.” 2007-2009.
8) GlaxoSmithKline: “ A phase III, double-blind, randomized, controlled, multi-center study to evaluate the efficacy of GlaxoSmithKline Biologicals' HPV-16/18 VLP/AS04 vaccine compared to hepatitis A vaccine as control in prevention of persistent HPV-16 or HPV-18 cervical infection and cervical neoplasia, administered intramuscularly according to a 0, 1, 6 month schedule in healthy females 15-25 years of age.” 2008-2010.
9) Amgen: “A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficiency and Safety of Adding Methotrexate to Etanercept in Subjects with Moderate to Severe Plaque Psoriasis” 2009-2011.
10) AiCuris: “A double-blind randomized placebo controlled dose-finding trial to investigate different doses of a new antiviral drug in subjects with gential HSV Type 2 infection.” 2009-2011.
11) Abbott Laboratories: “Phase II: A Phase 3, Multicenter study of the Efficacy and Safety of Long-term Adalimumab Treatment in Subjects with Moderate to Severe Plaque Psoriasis.” 2009-2011.
12) Maruho: “A Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Multi-Center Phase IIb Dose Finding Study of M518101 in Plaque Psoriasis Patients” 2010-2012.
13) Galderma: “A Phase 3 randomized, double blind, 12 week vehicle controlled, parallel group study assessing the efficacy and safety of CD5024 1 % cream versus vehicle cream in subjects with papulopustular rosacea, followed by a 40 week investigator blinded extension comparing the long term safety of CD5024 1% cream versus azelaic acid 15 % gel.” 2011-2012.
14) Novum: “A Randomized, Double-Blind, Placebo-Controlled, Multiple-Site, Study Comparing Metronidazole Topical Gel 1% (Taro Pharmaceutical Industries, Ltd.) to METROGEL (metronidazole gel) 1% (Galderma) in the Treatment of Moderate to Severe Rosacea” 2011-Present.
15) Novartis: “A Randomized, Double-Blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability and Long-Term Efficacy up to One Year in Subjects with Moderate to Severe Chronic Plaque-Type Psoriasis” 2011-Present.
16) Centocor: “A Phase 2 Multicenter, Randomized, Placebo- and Active- Comparator-Controlled, Dose-Ranging Trial to Evaluate CNTO1959 for the treatment of subjects with moderate to severe plaque-type psoriasis” 2011-Present.
17) Amgen: “Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects with Moderate to Severe Plaque Psoriasis Who Have Lost a Satisfactory Response to Adalimumab” 2011-Present.

Honors / Awards / Teaching / Lectures:

(2015) UCLA Distinguished Professor Teacher of the Year Award, Division of Dermatology
(2015) Georgia Regents University Jag20 Award Honoree: Emerging Alumni Leaders
(2010) Texas Dermatological Society Abstract/Poster award, “Zoster Complications”
(2009) Chief Dermatology Resident, University of Texas/MD Anderson Dermatology Residency Program
(2007) American Academy of Dermatology World Congress of Dermatology Travel Fellowship, Buenos Aires, Argentina

(2013-2014) Resident Pharmacology Board Review: Heavy Metals, Psoriasis Medications, Biologics, Retinoids
(2014) Dermatology Cadavar Lab instructor
(2014) Dermatology Medical Student Lecture
(2014) Dermatology Internal Medicine Residency Lecture

(2016) National Psoriasis Foundation - Allied Healthcare Provider Posriasis Recognition Program
(2014) UCLA community outreach/NPF lecture Psoriasis
(2014) Urology Grand Rounds: Common Dermatologic Manifestations
(2014) Women’s Health Initiative: Rashes in Dermatology
(2014) Women’s Health Initiative: Susncreen

Our Location
  • Facebook - Mosaic Dermatology
  • Instagram - Mosaic Dermatology

Beverly Hills:

   150 N Robertson Blvd #304
   Beverly Hills, CA 90211

Phone: 310-453-3101

Fax: 310-453-3104